Covira Surgical (Biotech)

Post-Surgical Infection Prevention

Claim My Business
Security Type
Common Stock
Technology, Healthcare & Medical
Min Investment
Offering Date
July 01, 2021
Expected Close Date
April 27, 2022
Target Raise
No. Investors
Security Price
Number of Employees
Short Term Debt
Cost of Goods
Long Term Debt
Net Income

Company Description

Covira is an early-stage biotech company, a spinout from The University of Chicago, focusing on the prevention of post-surgical infections. Covira’s approach to solving post-operative infections can be transformative to the field and even Business Worldwide Magazine named Covira Surgical Among the 2021- Top 20 Most Innovative Companies to Watch. This microbiome-focused company is based on the work of Dr. John Alverdy, MD, a professor of surgery, practicing gastrointestinal surgeon and world authority on the prevention of post-surgical infections. Covira has developed a proprietary solution phosphate (Pi) conjugated polyethylene glycol (PEG) polymer to reduce infection risk and related complications following surgical procedures.


StartEngine OWNERS Exclusive Click here to learn more

$250+ Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.

$1,000+ Investment
Tier 1
Invest $1,000+ , you will receive 5% bonus shares.

$5,000+ Investment
Tier 2
Invest $5,000+ , you will receive 10% bonus shares.

$10,000+ Investment
Tier 3
Invest $10,000+ , you will receive 15% bonus shares.

$25,000+ Investment
Tier 4
Invest $25,000+ , you will receive 20% bonus shares.

$100,000+ Investment
Tier 5
Invest $100,000+ , you will receive 25% bonus shares.

Key Deal Facts

Market Opportunity: Covira estimates the US total available market for Pi-PEG's top three prioritized indications (Surgical Site Infections, Anastomotic Leak, Sepsis) to be $8.8B. The peak year net revenue forecast is projected to reach $2.5B by 2037 (Source: IQVIA).

Technology Platform: Pi-PEG is an orally administered anti-virulence agent to prevent postoperative infections and their progression to sepsis.

Management Team: Founder is a preeminent surgeon-scientist and world leader in GI surgical infection research, CEO is a proven life science executive from J&J, Abbott and four prior startups including two in the biotech space culminating in strategic sales to larger multinational corporations.
Amount Raised : $838,665
Reveal the Score by Voting
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.

Security Description

Common stock is a security that represents ownership in a corporation.

Research Reports

No reports have been submitted

Become a Reporter